The Luminex 100/200 is a diagnostic detection platform based on the principles of flow cytometry. The system enables you to measure up to 100 analytes in a single microplate well, using small sample volumes. The system delivers fast and cost-effective bioassay results in different formats including nucleic acid assays, receptor-ligand assays, immunoassays and enzymatic assays. There are already several tests available for the detection of pathogens and last week the new respiratory viral assay xTAG RVP Fast got FDA clearance.
The xTAG Respiratory Viral Panel (RVP) gives clinical laboratories a diagnostic tool to help manage their patients with influenza-like symtoms. It targets simultaneously eight respiratory pathogens like Respiratory Syncytial Virus (RSV), Influenza A & B, Metapneumovirus (hMPV), Adenovirus and Rhinovirus.
In the recent European E. coli crisis staff at Kliniken der Stadt Köln Institut fur Pathologie, who use the Luminex 100/200 , have quickly adapted xTAG Gastrointestinal Pathogen Panel (GPP) as a first line screen. Luminex’s xTAG GPP can simultaneously detect fifteen of the most common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as E. coli, Campylobacter, Salmonella and C. difficile all within 5 hours. xTAG GPP received CE mark approval in May of 2011 from European regulatory authorities.
Press release: Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis …
Press release about FDA clearance of xTAG RVP Fast: Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
